Crimean-Congo hemorrhagic fever: Germany is conducting studies in Ukraine to isolate the most virulent strains of the disease, according to a Russian army official

At the end of June, Russian scientists discovered a new strain of Crimean-Congo hemorrhagic fever in the south of the country.

The German army conducted a study of fatal cases of Crimean-Congo fever in Ukraine in order to isolate the most pathogenic strains, indicated Igor Kirillov, the head of the troops of radiation protection, chemical and biological protection of the Russian Armed forces.

Read also :
It kills up to 40% of patients: what is this new strain of Crimean-Congo hemorrhagic fever, due to a Nairovirus, discovered in Russia?

“The Bundeswehr’s interest in Crimean-Congo fever is due to the fact that the lethality of the disease can reach 30% and that epidemics create the need for long and costly measures of treatment, prevention and special treatment”explained Kirillov, as reported by the Russian News Agency RIA Novosti.

Select strains that cause unknown symptoms

In addition, the military biologists of the Bundeswehr carried out in Ukraine a large-scale screening of the local population’s susceptibility to Crimean-Congo fever with the generalization of demographic, epidemiological and clinical data. This approach makes it possible to identify new regional genotypes of the virus and select strains that cause latent clinical formsnoted the general.

Read also :
New strain of Crimean-Congo hemorrhagic fever: what are the symptoms of this tick-borne disease that kills up to 40% of infected people?

At the end of June, Russian scientists announced the discovery of a new strain of Crimean-Congo hemorrhagic fever (CCHF).

Transmitted to humans primarily by ticks and cattle, according to the World Health Organization (WHO), Crimean-Congo hemorrhagic fever can be passed from person to person through contact with blood, secretions or other bodily fluids.

The case fatality rate for Crimean-Congo hemorrhagic fever, against which there is no preventive vaccine for humans or animals, is estimated at between “10 and 40%”, recalls the WHO. The disease is serious and causes high mortality in humansbut it rarely occurs.

Leave a Comment